World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
134
Citations
59674
World Ranking
2165
National Ranking
1224

Overview

William D. Figg is affiliated with the National Institutes of Health in the United States. Their research spans multiple fields within medicine and biochemistry, genetics, and molecular biology. The scientist has contributed extensively to oncology, pulmonary and respiratory medicine, molecular biology, genetics, and radiology, nuclear medicine, and imaging.

Their recent publications cover various aspects of cancer and diagnostics, including:

  • Selumetinib in Children with Inoperable Plexiform Neurofibromas, 2020, New England Journal of Medicine
  • Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress, 2021, Cancer Cell
  • COVID-19 Clinical Diagnostics and Testing Technology, 2020, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  • Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors, 2020, Journal of Clinical Oncology
  • Resistance to second-generation androgen receptor antagonists in prostate cancer, 2021, Nature Reviews Urology

William D. Figg frequently collaborates with a core group of coauthors, including:

  • Cody J. Peer (89 publications)
  • Seth M. Steinberg (52 publications)
  • Cindy H. Chau (34 publications)
  • James L. Gulley (31 publications)
  • Fatima Karzai (29 publications)

Their research appears regularly in several prominent scientific journals, with frequent contributions to:

  • Journal of Clinical Oncology (37 publications)
  • Blood (18 publications)
  • The Journal of Clinical Pharmacology (16 publications)
  • Cancer Research (8 publications)
  • The Oncologist (7 publications)

William D. Figg's main fields of study include Medicine, with 430 publications, and Biochemistry, Genetics, and Molecular Biology, accounting for 118 publications. Their subfields of focus reflect a concentration on:

  • Oncology (113 publications)
  • Pulmonary and Respiratory Medicine (82 publications)
  • Molecular Biology (75 publications)
  • Genetics (48 publications)
  • Radiology, Nuclear Medicine, and Imaging (35 publications)

The scientist's work covers a range of main topics, guiding cancer research and treatment strategies, notably in:

  • Prostate Cancer Treatment and Research (90 publications)
  • Cancer Immunotherapy and Biomarkers (56 publications)
  • Chronic Lymphocytic Leukemia Research (44 publications)
  • Lymphoma Diagnosis and Treatment (36 publications)
  • Radiopharmaceutical Chemistry and Applications (32 publications)
  • Lung Cancer Research Studies (28 publications)
  • Multiple Myeloma Research and Treatments (28 publications)

Best Publications

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

    Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris

  • Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

    Glenn J. Bubley;Michael Carducci;William Dahut;Nancy Dawson

  • Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

    Kevin C. Conlon;Enrico Lugli;Hugh C. Welles;Hugh C. Welles;Steven A. Rosenberg

  • Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

    Richard L. Piekarz;Robin Frye;Maria Turner;John J. Wright

  • Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.

    Austin G. Duffy;Susanna V. Ulahannan;Oxana Makorova-Rusher;Osama Rahma

  • Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

    Victor Sandor;Susan Bakke;Robert W Robey;Min H Kang

  • Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents

    Alex Sparreboom;Michael C. Cox;Milin R. Acharya;William D. Figg

  • Antibody–drug conjugates for cancer

    Cindy H Chau;Patricia S Steeg;William D Figg

  • Angiogenesis inhibitors: current strategies and future prospects.

    Kristina M. Cook;William D. Figg

  • Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas

    Howard A. Fine;William D. Figg;Kurt Jaeckle;Patrick Y. Wen

  • Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

    Alex Sparreboom;Charity D. Scripture;Vuong Trieu;Paul J. Williams

  • Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer

    Elisabetta Mueller;Matthew Smith;Pasha Sarraf;Todd Kroll

  • Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

    Richard L. Piekarz;Robin Frye;H. Miles Prince;Mark H. Kirschbaum

  • Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

    A M Senderowicz;D Headlee;S F Stinson;R M Lush

  • Selumetinib in Children with Inoperable Plexiform Neurofibromas

    Andrea M. Gross;Pamela L. Wolters;Eva Dombi;Andrea Baldwin

  • Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

    Qin C. Ryan;Donna Headlee;Milin Acharya;Alex Sparreboom

  • Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer

    Alain Thibault;Dvorit Samid;Dvorit Samid;Anne C. Tompkins;William D. Figg

  • Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

    William L. Dahut;James L. Gulley;Philip M. Arlen;Yinong Liu

  • Drug interactions in cancer therapy.

    Charity D. Scripture;William D. Figg

  • A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-independent Prostate Cancer

    William D. Figg;William Dahut;Paul Duray;Michael Hamilton

Frequent Co-Authors

Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
James L. Gulley
James L. Gulley National Institutes of Health
Alex Sparreboom
Alex Sparreboom The Ohio State University
Eddie Reed
Eddie Reed National Institutes of Health
Philip M. Arlen
Philip M. Arlen National Institutes of Health
David Venzon
David Venzon National Institutes of Health
Jane B. Trepel
Jane B. Trepel National Institutes of Health
Elise C. Kohn
Elise C. Kohn National Institutes of Health
Susan E. Bates
Susan E. Bates Columbia University
Peter L. Choyke
Peter L. Choyke National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online healthcare degrees can be a flexible and affordable way to advance your medical career in the USA. Many aspiring nurses and healthcare professionals are looking for the cheapest dnp programs online to save on tuition while still gaining the credentials needed for leadership roles.

One key consideration is understanding the average cost of rn to bsn programs. Costs can vary greatly, so researching affordable and accredited options can make a significant difference in your investment and future earnings.

If you’re transitioning into nursing without a prior nursing background, direct msn programs online offer accelerated pathways. These programs are designed for non-nursing graduates and can help you fast-track into advanced nursing roles.

Finally, prospective students often look for easy nursing schools to get into to maximize their chances of acceptance. These schools may offer flexible admission requirements and can be ideal for students starting out or looking for a career change in healthcare.

Best Scientists Citing William D. Figg

Trending Scientists

Recently Published Articles